Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Aims:To investigate the safety of oral iron therapy in pregnant women with iron-deficiency anemia (IDA) in the real world.Methods:A retrospective analysis was performed on 1792 pregnant patients with IDA who received oral iron supplements from 12 hospitals in Shandong Province from 1 April to 31 June 2021; follow-up and adverse reactions were recorded. They were divided into six groups according to the treatment drugs.Results:The overall adverse reaction rate was 15.4%, and the main adverse reaction site was the digestive system. The incidence of all kinds of oral iron adverse reactions from high to low in order: compound ferrous sulfate and folic acid tablets (21.88%); iron proteinsuccinylate oral solution (20.90%); ferrous succinate tablets (19.76%); ferrous succinate sustained-release tablets (18.00%); iron polysaccharide complex capsule (12.06%); and iron dextran oral solution (6.94%). It was found that there was a significant difference in the incidence of adverse reactions among the six drugs (p < 0.05). Pairwise comparison showed that the incidence of adverse reactions was higher in the iron proteinsuccinylate oral solution than that in the iron polysaccharide complex capsule (p 0.05), but there was a significant difference in the incidence of adverse reactions in different gestational ages (p < 0.05). In Adverse Drug Reaction (ADR) patients, the adverse reaction result of most patients is recovery or improvement, and there was no serious adverse reaction outcome such as sequela and death.Conclusion:All the adverse reactions of oral iron were mainly gastrointestinal adverse reactions, and no heavy adverse reactions were found. Iron proteinsuccinylate oral solution has a higher incidence of adverse reactions than iron polysaccharide complex capsule. The results showed that oral iron was safer for anemia patients during pregnancy.Plain language summarySafety of oral iron in the treatment of iron-deficiency anemia during pregnancyIntroduction: The safety of different oral iron agents varies. At present, the safety evaluation of iron supplements in the treatment of anemia during pregnancy is mainly focused on intravenous iron supplements, and there is no comprehensive study on the safety of commonly used oral iron supplements. This study compared the safety of six commonly used oral iron supplements in the treatment of iron-deficiency anemia during pregnancy, aiming to provide a reference for clinical medication.Methods: We conducted a study involving 1792 patients in 12 hospitals in Shandong Province from 1 April to 31 June 2021.Results: Among the six groups, 276 ADR patients reported 302 adverse reactions. There were significant differences in the rates of adverse reactions among the six oral iron agents, and the incidence of adverse reactions in the iron proteinsuccinylate oral solution was significantly higher than that of iron polysaccharide complex capsules. The main incidence of adverse reactions was constipation (6.96%), and most of the outcomes were cured or improved.Conclusion: In this study, there were no heavy adverse reactions. The incidence of adverse reactions of iron proteinsuccinylate oral was higher than that of iron polysaccharide compound capsule. The results showed that oral iron had a good safety in patients with anemia during pregnancy.

[Tolerability of iron preparation Actiferol Fe® in children treated for iron deficiency anemia]

Analysis of the Effect of Iron Dextran Oral Liquid on Pediatric Nutritional Iron Deficiency Anemia

Tolerability of different oral iron supplements: a systematic review

The Effectiveness and Side Effects of Ferrous Lactate Tablets for Patients with Iron Deficiency Anemia

Iron bioavailability from commercially available iron supplements

Comparative Study of Gastrointestinal Tract and Liver Toxicity of Ferrous Sulfate, Iron Amino Chelate and Iron Polymaltose Complex in Normal Rats

Intestinal Absorption Study of a Granular Form of Ferric Pyrophosphate

Pharmacological and toxicological studies on an iron succinyl-protein complex (ITF282) for oral treatment of iron deficiency anemia.

Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate

Food Supplements Containing Iron—Comparison of Actual Content with Declared Content and Health Consequences

TREATMENT OF IRON DEFICIENCY ANEMIA IN CHILDREN BY IRON SUPPLEMENTATION TWICE WEEKLY AND WEEKLY

Tolerability of Oral Supplementation with Microencapsulated Ferric Saccharate Compared to Ferrous Sulphate in Healthy Premenopausal Woman: A Crossover, Randomized, Double-Blind Clinical Trial

Comparative Evaluation of Intestinal Absorption and Functional Value of Iron Dietary Supplements and Drug with Different Delivery Systems

Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate

The Effect Of Iron Fortification On Iron (Fe) Status And Inflammation: A Randomized Controlled Trial

Oral iron supplementation: new formulations, old questions

Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study

Low-Dose Iron is Safer, Tolerable and Equally Effective to High-Dose Iron in Improving Iron Status in Mild-Anemic Female Participants

Mixture of Ferric Sodium Ethylenediaminetetraacetate (NaFeEDTA) and Ferrous Sulfate: An Effective Iron Fortificant for Complementary Foods for Young Chinese Children

A rapid, simple questionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation